Swiss regulatory aspects and evaluation considerations for ATMPs and other nucleic acid-based products such as mRNA-based vaccines

Vaccine Insights 2024; 3(3), 91–95

DOI: 10.18609/vac.2023.018

Published: 15 May
Julia Djonova

"Swissmedic is taking various measures to respond to innovation in order to provide appropriate support for developers and meet the expectations of industry and patient...”